Next Article in Journal
Calcium Channel Blockers as Tocolytics: Principles of Their Actions, Adverse Effects and Therapeutic Combinations
Next Article in Special Issue
Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
Previous Article in Journal
FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver
Previous Article in Special Issue
Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 6
Issue 5
10.3390/ph6050681
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Evolution of Biologics Screening Technologies

by
Peter Cariuk
*,
Matthew J. Gardener
and
Tristan J. Vaughan
MedImmune Ltd, Milstein Building, Granta Park, Cambridge CB21 6GH, UK
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(5), 681-688; https://doi.org/10.3390/ph6050681
Submission received: 5 February 2013 / Revised: 23 April 2013 / Accepted: 8 May 2013 / Published: 14 May 2013
(This article belongs to the Special Issue Biologics)
Browse Figures
Versions Notes

Abstract

Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug discovery has matured significantly and is today investing earlier in new technologies that commercial suppliers are now developing specifically to meet the growing needs of large molecule screening. Here, we review the evolution of screening and automation technologies employed in antibody discovery and highlight the benefits that these changes have brought.
Keywords: high throughput screening; assay technologies; therapeutic antibodies high throughput screening; assay technologies; therapeutic antibodies
Graphical Abstract

Share and Cite

MDPI and ACS Style

Cariuk, P.; Gardener, M.J.; Vaughan, T.J. Evolution of Biologics Screening Technologies. Pharmaceuticals 2013, 6, 681-688. https://doi.org/10.3390/ph6050681

AMA Style

Cariuk P, Gardener MJ, Vaughan TJ. Evolution of Biologics Screening Technologies. Pharmaceuticals. 2013; 6(5):681-688. https://doi.org/10.3390/ph6050681

Chicago/Turabian Style

Cariuk, Peter, Matthew J. Gardener, and Tristan J. Vaughan. 2013. "Evolution of Biologics Screening Technologies" Pharmaceuticals 6, no. 5: 681-688. https://doi.org/10.3390/ph6050681

APA Style

Cariuk, P., Gardener, M. J., & Vaughan, T. J. (2013). Evolution of Biologics Screening Technologies. Pharmaceuticals, 6(5), 681-688. https://doi.org/10.3390/ph6050681

Article Metrics

Back to TopTop